Despite impressive innovations in medicine, most advanced-stage cancers still carry a grim prognosis. Developing more ...

CAR T-cell therapy is considered a milestone in personalized cancer treatment. In this approach, a patient's own immune cells ...

ZFTA–RELA is the cancer-promoting protein product of a gene fusion. Analyses of accessible sites in the DNA–protein complex chromatin in developing mice show that ZFTA–RELA binds to chromatin modules ...

The partnership will automate manufacturing of ProT-096, a personalized progenitor T-cell therapy for refractory leukemia and ...

A national team of cancer researchers led by Drs. Kenneth Shroyer and Natalia Marchenko at Stony Brook Medicine, and Dr.

Immunotherapy, which uses programmed immune cells to selectively destroy cancer cells, has transformed cancer treatment. However, cancer cells have developed immune evasion strategies, leading to poor ...

Researchers at The University of Texas Medical Branch (UTMB) have identified how a key enzyme called ATR protects DNA from ...

The project is being led by Danielle Jex, a senior lecturer in immunology, and will investigate whether chemical signals ...

Every human cell is surrounded by a sugar coating known as the glycocalyx. It not only interacts with its environment but ...

Scientists have made astonishing progress in treating one of the deadliest cancers.

Last month, Revolution Medicines’ RAS inhibitor doubled survival in a Phase 3 pancreatic cancer trial. On the biotech’s heels are Immuneering, Actuate Therapeutics, Erasca and more, looking to improve ...